AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6189581 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy for total group of patients
Number of subjects: 225
Study 6189581 — intervention group
Group type: EXPERIMENTAL
Intervention: Median survival for solitary bone metastases from prostatic primary
Number of subjects: 225
Study 6189581 — intervention group
Group type: EXPERIMENTAL
Intervention: Median survival for multiple metastatic sites
Number of subjects: 225
Study 31841515 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybridization of C. nouraguensis females and C. becei males
Number of subjects: 0
Study 30571423 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete reperfusion after endovascular thrombectomy
Number of subjects: 381
Study 26768131 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitative tutoring (f)
Number of subjects: 0
Study 26768131 — intervention group
Group type: COMPARATOR
Intervention: Non-facilitative tutoring (nf)
Number of subjects: 0
Study 24145045 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocked practice
Number of subjects: 36
Study 24145045 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial practice
Number of subjects: 36
Study 24145045 — intervention group
Group type: COMPARATOR
Intervention: No practice (Control)
Number of subjects: 36
Study 21339433 — intervention group
Group type: EXPERIMENTAL
Intervention: Casopitant plus ondansetron (oral casopitant 50 mg + intravenous ondansetron 4 mg)
Number of subjects: 484
Study 21339433 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron only (intravenous ondansetron 4 mg)
Number of subjects: 484
Study 19900234 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg twice daily
Number of subjects: 51
Study 19900234 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline 50 mg at night
Number of subjects: 51
Study 17034288 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture to the contralateral ST36 acupuncture point (right side)
Number of subjects: 40
Study 17034288 — intervention group
Group type: COMPARATOR
Intervention: Electroacupuncture to the ipsilateral ST36 acupuncture point (left side)
Number of subjects: 40
Study 15354947 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse intravenous cyclophosphamide
Number of subjects: 28
Study 15354947 — intervention group
Group type: COMPARATOR
Intervention: Daily oral cyclophosphamide
Number of subjects: 28
Study 10651841 — intervention group
Group type: EXPERIMENTAL
Intervention: rhEPO plus intravenous iron sucrose (group 1)
Number of subjects: 60
Study 10651841 — intervention group
Group type: COMPARATOR
Intervention: rhEPO placebo plus intravenous iron sucrose (group 2)
Number of subjects: 60
Study 10651841 — intervention group
Group type: COMPARATOR
Intervention: oral iron alone (group 3)
Number of subjects: 60
Study 9580102 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoxsuprine (50 mg in 250 ml of DW5%)
Number of subjects: 50
Study 9580102 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoxsuprine
Number of subjects: 50
Study 8160562 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg once daily
Number of subjects: 38
Study 8160562 — intervention group
Group type: COMPARATOR
Intervention: Cetirizine 20 mg (10 mg twice a day)
Number of subjects: 38
Study 3511182 — intervention group
Group type: EXPERIMENTAL
Intervention: Urabe Am 9‐Schwarz vaccine
Number of subjects: 400
Study 3511182 — intervention group
Group type: COMPARATOR
Intervention: Jeryl Lynn‐Moraten vaccine
Number of subjects: 400
Study 3511182 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 400
Study 29483078 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care testing (POCT) using Flexicult™ SSIUrinary Kit
Number of subjects: 329
Study 29483078 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 329
Study 29483078 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care testing (POCT)
Number of subjects: 329
Study 29483078 — intervention group
Group type: COMPARATOR
Intervention: Point-of-care testing (POCT) and Standard care
Number of subjects: 329
Study 27470259 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive-expressive group (SEG) therapy
Number of subjects: 157
Study 27470259 — intervention group
Group type: EXPERIMENTAL
Intervention: Body-mind-spirit (BMS) intervention
Number of subjects: 157
Study 27470259 — intervention group
Group type: COMPARATOR
Intervention: Social support control group
Number of subjects: 157
Study 25240070 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted interpersonal psychotherapy
Number of subjects: 113
Study 25240070 — intervention group
Group type: COMPARATOR
Intervention: Health education
Number of subjects: 113
Study 22211699 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg daily
Number of subjects: 6415
Study 21054990 — intervention group
Group type: EXPERIMENTAL
Intervention: Tecnis ZM900 multifocal intraocular lens (TMF)
Number of subjects: 73
Study 21054990 — intervention group
Group type: COMPARATOR
Intervention: Restor SA60D3 multifocal intraocular lens (Restor)
Number of subjects: 73
Study 18207461 — intervention group
Group type: EXPERIMENTAL
Intervention: Level II ultrasonography
Number of subjects: 150
Study 18207461 — intervention group
Group type: COMPARATOR
Intervention: Level III ultrasonography
Number of subjects: 150
Study 18515465 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 0
Study 18515465 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15188939 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive patients receiving contemporary medical therapy
Number of subjects: 3326
Study 15188939 — intervention group
Group type: COMPARATOR
Intervention: Non-hypertensive patients receiving contemporary medical therapy
Number of subjects: 3326
Study 12363115 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole 15 mg/day
Number of subjects: 414
Study 12363115 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 10 mg/day
Number of subjects: 414
Study 12363115 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 414
Study 12363115 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole 15 mg/day and Haloperidol 10 mg/day
Number of subjects: 414
Study 12363115 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 414
Study 12363115 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 414
Study 9389264 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide at 0 vol.%
Number of subjects: 64
Study 9389264 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide at 20 vol.%
Number of subjects: 64
Study 9389264 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide at 40 vol.%
Number of subjects: 64
Study 9389264 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide at 60 vol.%
Number of subjects: 64
Study 9389264 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide at 45 vol.%
Number of subjects: 64
Study 7947240 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO (200 units/kg intravenous bolus daily) for 28 days or until Hct of 35% reached
Number of subjects: 10
Study 7947240 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO treatment
Number of subjects: 10
Study 7947240 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified treatment)
Number of subjects: 10
Study 3332575 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS, 30 or 60 mg daily
Number of subjects: 0
Study 3332575 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide, 25 or 50 mg daily
Number of subjects: 0
Study 3332575 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11739337 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical industry support
Number of subjects: 314
Study 11739337 — intervention group
Group type: COMPARATOR
Intervention: Non-industry support
Number of subjects: 314
Study 11739337 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study outcomes
Number of subjects: 314
Study 31718757 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher deprivation score (multidimensional poverty index)
Number of subjects: 323
Study 31718757 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher deprivation score (quintiles)
Number of subjects: 323
Study 31718757 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower self-reported income (quintiles)
Number of subjects: 323
Study 30075959 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-sternotomy (MS)
Number of subjects: 222
Study 30075959 — intervention group
Group type: COMPARATOR
Intervention: Full median sternotomy (FS)
Number of subjects: 222
Study 26305413 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic pole walking (NPW) training
Number of subjects: 70
Study 26305413 — intervention group
Group type: COMPARATOR
Intervention: Traditional treadmill training (TT)
Number of subjects: 70
Study 24697872 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral terbinafine for 2 weeks and topical terbinafine and 10% urea ointment for 4 weeks
Number of subjects: 0
Study 24697872 — intervention group
Group type: COMPARATOR
Intervention: Topical terbinafine and 10% urea ointment for 12 weeks
Number of subjects: 0
Study 22051697 — intervention group
Group type: EXPERIMENTAL
Intervention: Variants in the CRTAM gene associated with low vitamin D levels
Number of subjects: 987
Study 22051697 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional studies on cell lines
Number of subjects: 987
Study 20142572 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated telephone outreach with speech recognition (ATO‐SR) - a single interactive outreach call
Number of subjects: 20938
Study 20142572 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 20938
Study 18271228 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (needling method at Baihui (GV 20), Shenting (GV 24), Shenmen (HT 7))
Number of subjects: 46
Study 18271228 — intervention group
Group type: COMPARATOR
Intervention: Estazolam (oral administration)
Number of subjects: 46
Study 16218175 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous fat transfer (AFT)
Number of subjects: 59
Study 16218175 — intervention group
Group type: COMPARATOR
Intervention: Polylactic acid (PLA)
Number of subjects: 59
Study 16218175 — intervention group
Group type: COMPARATOR
Intervention: Polyacrylamide hydrogel (PAAG)
Number of subjects: 59
Study 12165551 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-10
Number of subjects: 329
Study 10102158 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous immunoglobulin (HDIVIG) therapy (1 g kg(‐1), over 4 h) with phototherapy
Number of subjects: 116
Study 10102158 — intervention group
Group type: COMPARATOR
Intervention: Conventional phototherapy alone
Number of subjects: 116
Study 8896153 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI examination of supraspinatus tendons
Number of subjects: 4
Study 8896153 — intervention group
Group type: COMPARATOR
Intervention: MRI examination of healthy volunteers
Number of subjects: 4
Study 2197716 — intervention group
Group type: EXPERIMENTAL
Intervention: inpatient family intervention (IFI)
Number of subjects: 92
Study 2197716 — intervention group
Group type: COMPARATOR
Intervention: multimodal hospital treatment without IFI
Number of subjects: 92
Study 2197716 — intervention group
Group type: EXPERIMENTAL
Intervention: multimodal hospital treatment with IFI
Number of subjects: 92
Study 21504 — intervention group
Group type: EXPERIMENTAL
Intervention: HC 20‐511 4 mg daily
Number of subjects: 50
Study 21504 — intervention group
Group type: EXPERIMENTAL
Intervention: HC 20‐511 2 mg daily
Number of subjects: 50
Study 21504 — intervention group
Group type: COMPARATOR
Intervention: Cyproheptadine (Periactin) 8 mg daily
Number of subjects: 50
Study 31296834 — intervention group
Group type: EXPERIMENTAL
Intervention: CR and IMT (Inspiratory Muscle Training)
Number of subjects: 90
Study 31296834 — intervention group
Group type: COMPARATOR
Intervention: CR only
Number of subjects: 90
Study 31296834 — intervention group
Group type: COMPARATOR
Intervention: IMT only
Number of subjects: 90
Study 29048182 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking abstinence on Day 1 (D1)
Number of subjects: 125
Study 29048182 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking abstinence on Day 3 (D3)
Number of subjects: 125
Study 29048182 — intervention group
Group type: EXPERIMENTAL
Intervention: Craving during the follicular phase
Number of subjects: 125
Study 29048182 — intervention group
Group type: EXPERIMENTAL
Intervention: Craving during the luteal phase
Number of subjects: 125
Study 25504143 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management support (SMS) tool with instruction to link stressful situations with healthy snack alternatives
Number of subjects: 0
Study 25504143 — intervention group
Group type: COMPARATOR
Intervention: Stress management support (SMS) tool without linking instruction (control)
Number of subjects: 0
Study 25504143 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management support (SMS) tool with linking instruction (experimental)
Number of subjects: 0
Study 24734908 — intervention group
Group type: COMPARATOR
Intervention: Setipiprant 2000 mg single dose
Number of subjects: 16
Study 24734908 — intervention group
Group type: COMPARATOR
Intervention: Setipiprant 500 mg b.i.d. for 5.5 days
Number of subjects: 16
Study 24734908 — intervention group
Group type: COMPARATOR
Intervention: Setipiprant 1000 mg b.i.d. for 5.5 days
Number of subjects: 16
Study 24734908 — intervention group
Group type: COMPARATOR
Intervention: Setipiprant (single and multiple doses)
Number of subjects: 16
Study 24734908 — intervention group
Group type: COMPARATOR
Intervention: Setipiprant with food
Number of subjects: 16
Study 24734908 — intervention group
Group type: COMPARATOR
Intervention: Urinary excretion of unchanged setipiprant
Number of subjects: 16
Study 22946083 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary intervention for mothers of children newly diagnosed with cancer
Number of subjects: 52
Study 22946083 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 52
Study 19685416 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (10 weeks of progressive strength training)
Number of subjects: 74
Study 19685416 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 74
Study 16824797 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized basketball training (SP)
Number of subjects: 27
Study 16824797 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed basketball plus conditioning training (MX)
Number of subjects: 27
Study 16824797 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study 15001199 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 2 mg plus Indapamide 0.625 mg
Number of subjects: 201
Study 15001199 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 50 mg
Number of subjects: 201
Study 15001199 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril/Indapamide
Number of subjects: 201
Study 15187802 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemoline (75 to 112.5 mg, titrated over 4 weeks to a single morning dose for 12 weeks)
Number of subjects: 69
Study 15187802 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemoline
Number of subjects: 69
Study 15187802 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 15187802 — intervention group
Group type: COMPARATOR
Intervention: Pemoline and Placebo
Number of subjects: 69
Study 11328223 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg mifepristone followed by gemeprost 1 mg vaginally
Number of subjects: 896
Study 11328223 — intervention group
Group type: COMPARATOR
Intervention: 600 mg mifepristone followed by gemeprost 1 mg vaginally
Number of subjects: 896
Study 11328223 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg mifepristone
Number of subjects: 896
Study 11328223 — intervention group
Group type: COMPARATOR
Intervention: 600 mg mifepristone
Number of subjects: 896
Study 9219072 — intervention group
Group type: EXPERIMENTAL
Intervention: Various interventions identified in RCTs
Number of subjects: 56
Study 9219072 — intervention group
Group type: COMPARATOR
Intervention: Electronic searches for trials
Number of subjects: 56
Study 7955441 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH) replacement therapy (0.018 U/kg/day for 1 month followed by 0.036 U/kg/day for 1 month)
Number of subjects: 18
Study 7955441 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH) replacement therapy
Number of subjects: 18
Study 7955441 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study 3298936 — intervention group
Group type: EXPERIMENTAL
Intervention: GIP (2 pmol/kg/min)
Number of subjects: 18
Study 3298936 — intervention group
Group type: COMPARATOR
Intervention: Isotonic NaCl
Number of subjects: 18
Study 30286455 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol Acetate
Number of subjects: 0
Study 30286455 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin and Megestrol
Number of subjects: 0
Study 27848149 — intervention group
Group type: EXPERIMENTAL
Intervention: High managerial experience (HME)
Number of subjects: 68
Study 25818264 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional injection of collagenase Clostridium histolyticum (CCH) 0.58 mg
Number of subjects: 1044
Study 25818264 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 1044
Study 24340995 — intervention group
Group type: EXPERIMENTAL
Intervention: HyperHAES solution used during prolonged veno-venous haemofiltration
Number of subjects: 0
Study 21516302 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib (12 weeks)
Number of subjects: 115
Study 21516302 — intervention group
Group type: COMPARATOR
Intervention: Placebo (12 weeks)
Number of subjects: 115
Study 18292446 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural neostigmine (1 microg/kg)
Number of subjects: 45
Study 18292446 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 45
Study 16825047 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineralized collagen bone graft substitute combined with bone marrow aspirate
Number of subjects: 25
Study 16825047 — intervention group
Group type: COMPARATOR
Intervention: Iliac crest autograft
Number of subjects: 25
Study 16825047 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 25
Study 12955428 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous octreotide administered 1 hour before stenting and every 8 hours for 3 weeks
Number of subjects: 148
Study 12955428 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered 1 hour before stenting and every 8 hours for 3 weeks
Number of subjects: 148
Study 12955428 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous octreotide
Number of subjects: 148
Study 12955428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study 10757623 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg three times daily
Number of subjects: 228
Study 10757623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 228
Study 8631519 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive physiotherapy
Number of subjects: 44
Study 8631519 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 44
Study 8631519 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific measurable goals
Number of subjects: 44
Study 8631519 — intervention group
Group type: COMPARATOR
Intervention: Broad, generalised aims
Number of subjects: 44
Study 1581773 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracospinal hyperostosis
Number of subjects: 85
Study 1581773 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder hyperostosis
Number of subjects: 85
Study 1581773 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbow hyperostosis
Number of subjects: 85
Study 4082903 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased ratio of carbidopa to levodopa (1:4)
Number of subjects: 11
Study 4082903 — intervention group
Group type: COMPARATOR
Intervention: Standard ratio of carbidopa to levodopa (1:10)
Number of subjects: 11
Study 29973117 — intervention group
Group type: EXPERIMENTAL
Intervention: Education with fluorescent gel
Number of subjects: 96
Study 29973117 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive education
Number of subjects: 96
Study 29973117 — intervention group
Group type: COMPARATOR
Intervention: Normal education (control group)
Number of subjects: 96
Study 28323043 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose vitamin D3 (20,000 IU twice a week)
Number of subjects: 297
Study 28323043 — intervention group
Group type: COMPARATOR
Intervention: Standard dose (placebo)
Number of subjects: 297
Study 27411750 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary and alternative medicine (CAM) use at baseline
Number of subjects: 640
Study 27411750 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary and alternative medicine (CAM) use at 52 weeks
Number of subjects: 640
Study 27411750 — intervention group
Group type: EXPERIMENTAL
Intervention: CAM use at baseline
Number of subjects: 640
Study 27411750 — intervention group
Group type: EXPERIMENTAL
Intervention: CAM use
Number of subjects: 640
Study 24929430 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 563
Study 24929430 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 563
Study 24929430 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 563
Study 23107894 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (C, 20 then 40 mg/day)
Number of subjects: 30
Study 23107894 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (V, 160 then 320 mg/day)
Number of subjects: 30
Study 19295224 — intervention group
Group type: EXPERIMENTAL
Intervention: Real laser needle acupuncture (Laserneedle Computer-System), 8 sessions of 20 min each over 3 menstrual cycles.
Number of subjects: 48
Study 19295224 — intervention group
Group type: COMPARATOR
Intervention: Placebo laser needle acupuncture (no laser activity), 8 sessions of 20 min each over 3 menstrual cycles.
Number of subjects: 48
Study 17264716 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubes telescoped into catheters
Number of subjects: 0